Jenne Kyle 4
4 · IONIS PHARMACEUTICALS INC · Filed Apr 17, 2025
Insider Transaction Report
Form 4
Jenne Kyle
EVP, Chf GL Pdt Str Ofcr
Transactions
- Sale
Common Stock
2025-04-16$28.36/sh−3,016$85,534→ 11,199 total - Exercise/Conversion
Common Stock
2025-04-15+12,226→ 14,215 total - Exercise/Conversion
Restricted Stock Unit
2025-04-15−12,226→ 36,677 total→ Common Stock (12,226 underlying)
Footnotes (5)
- [F1]Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.
- [F2]The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.35 to $28.37 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
- [F4]Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.
- [F5]Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.